Abstract

The Macrophage Migration Inhibitory Factor (MIF) is an inflammatory cytokine that is overexpressed in a number of cancer types, with increased MIF expression often correlating with tumor aggressiveness and poor patient outcomes. In this study, we aimed to better understand the link between primary tumor expression of MIF and increased tumor growth. Using the MMTV-PyMT murine model of breast cancer, we observed that elevated MIF expression promoted tumor appearance and growth. Supporting this, we confirmed our previous observation that higher MIF expression supported tumor growth in the 4T1 murine model of breast cancer. We subsequently discovered that loss of MIF expression in 4T1 cells led to decreased cell numbers and increased apoptosis in vitro under reduced serum culture conditions. We hypothesized that this increase in cell death would promote detection by the host immune system in vivo, which could explain the observed impairment in tumor growth. Supporting this, we demonstrated that loss of MIF expression in the primary tumor led to an increased abundance of intra-tumoral IFNgamma-producing CD4+ and CD8+ T cells, and that depletion of T cells from mice bearing MIF-deficient tumors restored growth to the level of MIF-expressing tumors. Furthermore, we found that MIF depletion from the tumor cells resulted in greater numbers of activated intra-tumoral dendritic cells (DCs). Lastly, we demonstrated that loss of MIF expression led to a robust induction of a specialized form of cell death, immunogenic cell death (ICD), in vitro. Together, our data suggests a model in which MIF expression in the primary tumor dampens the anti-tumor immune response, promoting tumor growth.

Highlights

  • The Macrophage Migration Inhibitory Factor (MIF) was first described in the 1960’s as a T cell secreted factor capable of inhibiting the random migration of macrophages in vitro [1,2]

  • These data suggest that loss of MIF expression in the mammary tumor virus (MMTV)-PyMT model leads to a delay in tumor appearance and reduction in tumor growth

  • Our results demonstrate that tumor cell-derived MIF is responsible for several aspects of the anti-tumor immune response in tumor-bearing animals

Read more

Summary

Introduction

The Macrophage Migration Inhibitory Factor (MIF) was first described in the 1960’s as a T cell secreted factor capable of inhibiting the random migration of macrophages in vitro [1,2]. MIF has since been characterized as an inflammatory cytokine implicated in a number of diseases, including colitis and arthritis [3,4]. A role for MIF in the immunosuppressive tumor microenvironment. Institute (KNB); Farrow Fellowship (KNB); University of Virginia Cancer Center Support Grant P30 CA44579 from the National Cancer Institute (JVC); Women’s 4-miler Breast Cancer Research Fund from the University of Virginia Cancer Center (JVC); and Department of Pathology, University of Virginia School of Medicine (JVC)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call